Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CAR-T

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Baxalta makes $1.7bn play for slice of CAR-T market

Three-year alliance with Precision BioSciences to expand immuno-oncology portfolio

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

Merck Serono joins CAR-T race with $941m Intrexon deal

Will collaborate on therapy to recognise and attack antigens on tumour cells

- PMLiVE

Boehringer backs gene therapy firm Eyevensys

Invests in French eye disease specialist

- PMLiVE

Basilea’s Hans Christian Rohde takes up commercial role at uniQure

Will serve as gene therapy specialist's chief commercial officer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links